Cargando…
Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin
This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P‐gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2‐K), and 10 mg rosuvastatin (OATP1B1, OATP1B3, and BCRP) were...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102573/ https://www.ncbi.nlm.nih.gov/pubmed/27256812 http://dx.doi.org/10.1002/cpt.406 |
_version_ | 1782466446549319680 |
---|---|
author | Stopfer, P Giessmann, T Hohl, K Sharma, A Ishiguro, N Taub, ME Zimdahl‐Gelling, H Gansser, D Wein, M Ebner, T Müller, F |
author_facet | Stopfer, P Giessmann, T Hohl, K Sharma, A Ishiguro, N Taub, ME Zimdahl‐Gelling, H Gansser, D Wein, M Ebner, T Müller, F |
author_sort | Stopfer, P |
collection | PubMed |
description | This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P‐gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2‐K), and 10 mg rosuvastatin (OATP1B1, OATP1B3, and BCRP) were administered separately or as a cocktail in a randomized six‐period crossover trial in 24 healthy male volunteers. As a cocktail, relative bioavailabilities of digoxin and metformin and furosemide AUC(0‐tz) were similar to separate dosing. However, when administered as a cocktail the C(max) of furosemide was 19.1% lower and the C(max) and AUC(0‐tz) of rosuvastatin were 38.6% and 43.4% higher, respectively. In addition, the effects of increased doses of metformin or furosemide on the cocktail were investigated in 11 and 12 subjects, respectively. The cocktail explored in this trial has the potential to be used for the in vivo screening of transporter‐mediated drug–drug interactions. © 2016 American Society for Clinical Pharmacology and Therapeutics |
format | Online Article Text |
id | pubmed-5102573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51025732016-11-14 Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin Stopfer, P Giessmann, T Hohl, K Sharma, A Ishiguro, N Taub, ME Zimdahl‐Gelling, H Gansser, D Wein, M Ebner, T Müller, F Clin Pharmacol Ther Research This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P‐gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2‐K), and 10 mg rosuvastatin (OATP1B1, OATP1B3, and BCRP) were administered separately or as a cocktail in a randomized six‐period crossover trial in 24 healthy male volunteers. As a cocktail, relative bioavailabilities of digoxin and metformin and furosemide AUC(0‐tz) were similar to separate dosing. However, when administered as a cocktail the C(max) of furosemide was 19.1% lower and the C(max) and AUC(0‐tz) of rosuvastatin were 38.6% and 43.4% higher, respectively. In addition, the effects of increased doses of metformin or furosemide on the cocktail were investigated in 11 and 12 subjects, respectively. The cocktail explored in this trial has the potential to be used for the in vivo screening of transporter‐mediated drug–drug interactions. © 2016 American Society for Clinical Pharmacology and Therapeutics John Wiley and Sons Inc. 2016-07-29 2016-09 /pmc/articles/PMC5102573/ /pubmed/27256812 http://dx.doi.org/10.1002/cpt.406 Text en © 2016 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Stopfer, P Giessmann, T Hohl, K Sharma, A Ishiguro, N Taub, ME Zimdahl‐Gelling, H Gansser, D Wein, M Ebner, T Müller, F Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
title | Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
title_full | Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
title_fullStr | Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
title_full_unstemmed | Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
title_short | Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
title_sort | pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102573/ https://www.ncbi.nlm.nih.gov/pubmed/27256812 http://dx.doi.org/10.1002/cpt.406 |
work_keys_str_mv | AT stopferp pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT giessmannt pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT hohlk pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT sharmaa pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT ishiguron pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT taubme pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT zimdahlgellingh pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT gansserd pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT weinm pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT ebnert pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin AT mullerf pharmacokineticevaluationofadrugtransportercocktailconsistingofdigoxinfurosemidemetforminandrosuvastatin |